Aposcience AG

Founded

2008

Staff

13

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Focus

human health

Aposcience AG is unique in having developed a secretome-based regenerative therapy. The secretome is produced under GMP-conditions and was approved by the Austrian regulatory agency for a clinical phase II trial. Our product platform Aposec consists of two products: APO-1 - Aposec for internal diseases (acute myocardial infarction, spinal cord injury and stroke) APO-2 - Aposec for topical application (hard-healing wounds, diabetic ulcers)

R&D:Aposcience AG is currently conducting a clinical phase I/II trial for allogeneic APO-2 (ClinicalTrials.gov Identifier: NCT04277598 ). Autologous APO-2 has already been clinically evaluated in a phase I trial (ClinicalTrials.gov Identifier: NCT 02284360) If you are interested in our publications, consult www.aposcience.com --> News --> Key Publications